 |
 |
<---- Begin Forwarded Message ----> From: WE MOVE <[log in to unmask]> Subject: PD Drugs: Adverse Effects Date: Sun, 26 Dec 1999 21:50:03 -0600 1. Worsening of motor features of parkinsonism with olanzapine ES Molho, SA Factor Movement Disorders 1999;14:1014-1016 Retrospective evaluation of 12 PD patients on olanzapine for drug-induced psychosis showed that while nine had improved psychotic symptoms, nine also had worsening motor function, six dramatically so. Switch to other atypical neuroleptics (clozapine, quetiapine) improved motor function. The authors note that despite the limitations of the study, "the results reported here strongly suggest that the idea that olanzapine is free of extrapyramidal side effects should now be viewed with skepticism." 2. Low dose cabergoline induces interstitial pneumonitis W Frank, R Moritz, B Becke, R Pauli Eur Respir J 1999;14:968-970 A 65-year-old patient with PD of 12 years' duration developed interstitial pneumonitis four months after introduction of cabergoline (1 mg/day) into the treatment regimen. Extensive tests revealed no environmental or infectious cause for the symptoms, and discontinuation of the cabergoline led to almost complete resolution within two months. 3. Amantadine-induced peripheral neuropathy LM Shulman, A Minagar, K Sharma, WJ Weiner Neurology 1999;53:1862-1865 A 48-year-old patient with PD of 13 years' duration developed livedo reticularis within one year of beginning amantadine, which progressed over the next seven years, culminating in skin ulcers, distal weakness, and paresthesias. The patient was diagnosed with axonal peripheral neuropathy possibly secondary to amantadine. Discontinuation of amantadine led to gradual improvement in all symptoms, but worsening of motor performance. The authors recommend that amantadine be discontinued in patients with severe and chronic livedo reticularis. Copyright 1999 WE MOVE Editor: Richard Robinson ([log in to unmask]) E-MOVE archives, plus information on subscribing, are available at http://www.wemove.org/emove. To unsubscribe, send an e-mail to [log in to unmask], with "unsubscribe e-move" in the message body. E-MOVE is a service of WE MOVE (Worldwide Education and Awareness for Movement Disorders) 204 West 84th Street New York, NY 10024 TEL 800-437-MOV2 TEL 212-241-8567 FAX 212-987-7363 http://www.wemove.org <---- End Forwarded Message ---->